Xlife Sciences AG
Develops and commercializes early-stage life sciences research projects.
XLS | SW
Overview
Corporate Details
- ISIN(s):
- CH0461929603 (+1 more)
- LEI:
- 984500AH590BE88BB517
- Country:
- Switzerland
- Address:
- Talacker 35, 8001 Zürich
Description
Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2024-04-30 02:00 |
Xlife Sciences AG meldet starkes Portfolio-Wachstum und strategische Fortschrit…
|
German | HTML • 8.6 KB | ||
| 2024-04-23 07:00 |
Xlife Sciences AG Publishes 2023 Annual Report
|
English | HTML • 11.2 KB | ||
| 2024-04-23 02:00 |
Xlife Sciences AG Publishes 2023 Annual Report
|
English | HTML • 9.6 KB | ||
| 2024-04-23 02:00 |
Xlife Sciences AG veröffentlicht Geschäftsbericht 2023
|
German | HTML • 12.6 KB | ||
| 2024-04-03 17:00 |
Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Compa…
|
English | HTML • 11.8 KB | ||
| 2024-04-03 02:00 |
Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Compa…
|
English | HTML • 9.9 KB | ||
| 2024-04-03 02:00 |
Xlife Sciences AG verkündet Kooperationsvertrag zwischen ihrer Portfolio-Gesell…
|
German | HTML • 10.4 KB | ||
| 2024-02-05 07:00 |
Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Pa…
|
English | HTML • 11.8 KB | ||
| 2024-02-05 01:00 |
Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Pa…
|
English | HTML • 9.7 KB | ||
| 2024-02-05 01:00 |
Xlife Sciences AG erweitert die Zusammenarbeit mit der Gesundheitsbehörde von A…
|
German | HTML • 10.7 KB | ||
| 2023-12-29 17:45 |
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline
|
English | HTML • 8.4 KB | ||
| 2023-12-29 01:00 |
VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline
|
English | HTML • 6.8 KB | ||
| 2023-12-29 01:00 |
VERAXA Biotech AG übernimmt Synimmune GmbH zur Erweiterung des Krebsportfolios
|
German | HTML • 10.5 KB | ||
| 2023-12-22 07:00 |
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodia…
|
English | HTML • 10.3 KB | ||
| 2023-12-22 01:00 |
Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodia…
|
English | HTML • 8.5 KB |
Automate Your Workflow. Get a real-time feed of all Xlife Sciences AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xlife Sciences AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xlife Sciences AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-15 | N/A | Executive member | Buy | None | 6,000.00 CHF |
| 2022-06-15 | N/A | Executive member | Buy | None | 3,000.00 CHF |
| 2022-06-14 | N/A | Executive member | Buy | None | 15,500.00 CHF |
| 2022-06-10 | N/A | Executive member | Buy | None | 6,728.90 CHF |
| 2022-06-07 | N/A | Executive member | Buy | None | 34,800.00 CHF |
| 2022-06-03 | N/A | Executive member | Buy | None | 3,540.00 CHF |
| 2022-05-24 | N/A | Executive member | Buy | None | 3,400.00 CHF |
| 2022-05-17 | N/A | Executive member | Buy | None | 10,794.20 CHF |
| 2022-05-13 | N/A | Executive member | Buy | None | 3,690.00 CHF |
| 2022-05-10 | N/A | Executive member | Buy | None | 1,935.00 CHF |
Peer Companies
